You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. Abbott shares have dipped 0.7% in the past year. Estimates for the company’s 2024 earnings per share have remained constant at $4.67 in the past 30 days. ABT’s earnings beat estimates in three of the...
Quest Diagnostics reported fourth-quarter 2024 adjusted EPS of $2.23, which topped the Zacks Consensus Estimate by 1.8%. Revenues of $2.62 billion beat the Zacks Consensus Estimate by 1.9%. DGX carries a Zacks Rank #2 (Buy). You can seethe complete list of today’s Zacks #1 ...
In the fourth quarter of 2024, worldwide CAG Diagnostics’ recurring revenues increased 4% organically, supported by an average global net price improvement of approximately 4-4.5%, with the U.S. net price realization of approximately 3.5%. Also, recurring revenue growth was driven by 12% inter...
(Revision December 23, 2024) To view previous version,click here Welcome to IDEXX! Please know that we are committed to enhancing the health and well- being of pets, people, and livestock, and that by using IDEXX you are joining professionals worldwide who choose to use the world’s most...
Stock PricePrevious Close52 wk RangeMarket CapSharesAverage VolumeEPS $459.78 $460.56 $398.50 - $583.39 $37.6B 82.3M 652K $10.77 Idexx Laboratories Financials Summary As of 31-Dec-2024, Idexx Laboratories has a trailing 12-month revenue of $3.9B. In Thousands,USD TTM 31-Dec-2024 FY 2024...
Haemonetics has an estimated earnings growth rate of 27.1% for fiscal 2024 compared with the industry’s 17.2%. HAE’s earnings surpassed the Zacks Consensus Estimate in all the trailing four quarters, the average surprise being 19.39%. Its shares have rallied 3.8% against the industry’s 9.2%...